Is Retatrutide Better Than Mounjaro?
Retatrutide produced greater weight loss than tirzepatide (Mounjaro/Zepbound) in early clinical trials. Phase 2 data showed up to 24.2% body weight loss with retatrutide over 48 weeks, compared to approximately 20 to 22% with tirzepatide over 72 weeks. Both drugs are manufactured by Eli Lilly, but retatrutide adds a third receptor target and is not yet FDA approved.
Detailed Explanation
Mounjaro (tirzepatide) is a dual-agonist that targets GLP-1 and GIP receptors. It received FDA approval for type 2 diabetes in 2022 and is also marketed as Zepbound for chronic weight management. Tirzepatide represented a significant advance over single-agonist GLP-1 drugs like semaglutide.
Retatrutide builds on tirzepatide's dual-agonist approach by adding glucagon receptor activation, making it a triple-agonist. The glucagon component is designed to increase energy expenditure, promote fat oxidation, and reduce liver fat. This third mechanism may explain the additional weight loss observed in trials.
Clinical Trial Results Side by Side
In the SURMOUNT-1 trial, tirzepatide at its highest dose (15 mg) produced an average weight loss of 22.5% over 72 weeks in adults with obesity. In retatrutide's Phase 2 trial, the highest dose (12 mg) produced 24.2% weight loss in just 48 weeks, and the weight loss curve had not plateaued at the end of the study, suggesting even greater losses might occur with longer treatment.
This comparison is notable because retatrutide achieved slightly more weight loss in a considerably shorter time frame. However, these were different trials with different patient populations, making a precise comparison imperfect.
Eli Lilly's Product Strategy
Both drugs come from the same manufacturer. If retatrutide is approved, Eli Lilly will likely position it as a next-generation option rather than a direct replacement for tirzepatide. The two drugs may serve different patient segments based on factors like severity of obesity, metabolic comorbidities, tolerability, and cost.
Tirzepatide has the advantage of an established safety record, extensive real-world usage data, and existing insurance coverage pathways. Retatrutide will need to build this track record from scratch after approval.
What to Consider
- Mounjaro is available now. Tirzepatide can be prescribed today by licensed providers, while retatrutide is likely years away from reaching pharmacies.
- Phase 2 results may not fully predict Phase 3 outcomes. Larger trials sometimes produce different efficacy and safety results than smaller Phase 2 studies.
- The glucagon component is a double-edged sword. While it may boost weight loss, glucagon activation can raise blood sugar. This effect needs careful evaluation in patients with type 2 diabetes.
- Side effect profiles appear similar. Both drugs share the gastrointestinal side effects common to incretin-based therapies. Phase 3 data will clarify whether retatrutide's triple mechanism causes additional side effects.
- Individual response varies. Some patients respond better to certain receptor combinations. A physician can help determine which approach is most appropriate for your situation.
Related Questions
Take the Next Step
Mounjaro and other proven GLP-1 treatments are available right now through physician-supervised telehealth. FormBlends provides personalized consultations with licensed providers who can prescribe the best option for your weight loss goals. Start your free consultation today.